Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 17 | 2025 | 187 | 3.380 |
Why?
|
| Pneumococcal Infections | 6 | 2025 | 33 | 1.790 |
Why?
|
| Bacteremia | 3 | 2025 | 37 | 0.870 |
Why?
|
| Pneumococcal Vaccines | 4 | 2025 | 16 | 0.790 |
Why?
|
| Mass Casualty Incidents | 1 | 2020 | 2 | 0.680 |
Why?
|
| Physician's Role | 1 | 2020 | 40 | 0.660 |
Why?
|
| Child | 16 | 2025 | 3443 | 0.620 |
Why?
|
| Stroke | 5 | 2015 | 340 | 0.550 |
Why?
|
| Streptococcus pneumoniae | 3 | 2025 | 34 | 0.510 |
Why?
|
| Databases, Factual | 1 | 2015 | 341 | 0.410 |
Why?
|
| Brain Ischemia | 1 | 2015 | 189 | 0.400 |
Why?
|
| Child, Preschool | 8 | 2025 | 1546 | 0.330 |
Why?
|
| Hemoglobin, Sickle | 2 | 2023 | 11 | 0.330 |
Why?
|
| Blood Specimen Collection | 1 | 2010 | 12 | 0.330 |
Why?
|
| Bacteriological Techniques | 1 | 2010 | 15 | 0.330 |
Why?
|
| Vaccines, Conjugate | 3 | 2025 | 9 | 0.320 |
Why?
|
| Iron Overload | 1 | 2009 | 10 | 0.310 |
Why?
|
| Ferritins | 1 | 2009 | 63 | 0.300 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 67 | 0.290 |
Why?
|
| Immunity, Herd | 1 | 2008 | 2 | 0.280 |
Why?
|
| Infant | 6 | 2025 | 1175 | 0.280 |
Why?
|
| Meningococcal Vaccines | 1 | 2008 | 6 | 0.280 |
Why?
|
| Vaccination | 2 | 2021 | 355 | 0.270 |
Why?
|
| Fetal Blood | 1 | 2007 | 48 | 0.260 |
Why?
|
| Histocompatibility Testing | 2 | 2009 | 7 | 0.260 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2006 | 2 | 0.240 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2006 | 5 | 0.240 |
Why?
|
| Humans | 20 | 2025 | 43102 | 0.230 |
Why?
|
| Penicillins | 1 | 2003 | 10 | 0.210 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 1067 | 0.190 |
Why?
|
| Acute Chest Syndrome | 1 | 2021 | 2 | 0.180 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 58 | 0.170 |
Why?
|
| Influenza, Human | 1 | 2021 | 92 | 0.160 |
Why?
|
| Commerce | 1 | 2020 | 95 | 0.160 |
Why?
|
| Adolescent | 7 | 2025 | 6081 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2025 | 2544 | 0.120 |
Why?
|
| Hemoglobin C | 1 | 2015 | 1 | 0.120 |
Why?
|
| Neonatal Screening | 1 | 2015 | 25 | 0.120 |
Why?
|
| Male | 9 | 2025 | 23409 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 3 | 2025 | 432 | 0.120 |
Why?
|
| Gene Frequency | 1 | 2015 | 206 | 0.110 |
Why?
|
| Female | 9 | 2025 | 24698 | 0.110 |
Why?
|
| Patient Discharge | 1 | 2015 | 128 | 0.110 |
Why?
|
| Incidence | 3 | 2024 | 1078 | 0.110 |
Why?
|
| Risk Factors | 5 | 2024 | 3994 | 0.110 |
Why?
|
| United States | 3 | 2024 | 5205 | 0.100 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 9 | 0.090 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2012 | 28 | 0.090 |
Why?
|
| Prognosis | 2 | 2025 | 861 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2012 | 81 | 0.090 |
Why?
|
| Democratic Republic of the Congo | 1 | 2010 | 6 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2012 | 575 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2009 | 368 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 201 | 0.080 |
Why?
|
| Malaria, Falciparum | 1 | 2011 | 90 | 0.080 |
Why?
|
| Graft vs Host Disease | 2 | 2009 | 15 | 0.080 |
Why?
|
| Gonadal Disorders | 1 | 2009 | 1 | 0.080 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2010 | 98 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2009 | 19 | 0.080 |
Why?
|
| Deferoxamine | 1 | 2009 | 17 | 0.080 |
Why?
|
| Siderophores | 1 | 2009 | 15 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 27 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2009 | 95 | 0.080 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 32 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 3156 | 0.070 |
Why?
|
| ROC Curve | 1 | 2009 | 159 | 0.070 |
Why?
|
| Immunization Schedule | 1 | 2008 | 9 | 0.070 |
Why?
|
| Probability | 1 | 2008 | 82 | 0.070 |
Why?
|
| Serotyping | 2 | 2006 | 37 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 734 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2008 | 863 | 0.070 |
Why?
|
| Georgia | 1 | 2008 | 192 | 0.070 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2006 | 3 | 0.060 |
Why?
|
| Virginiamycin | 1 | 2006 | 1 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 518 | 0.060 |
Why?
|
| Blood Transfusion | 2 | 2006 | 31 | 0.060 |
Why?
|
| Liver | 1 | 2009 | 511 | 0.060 |
Why?
|
| HLA-DR Antigens | 1 | 2006 | 23 | 0.060 |
Why?
|
| Health Status | 1 | 2009 | 442 | 0.060 |
Why?
|
| Registries | 1 | 2008 | 437 | 0.060 |
Why?
|
| Age Factors | 1 | 2008 | 1154 | 0.050 |
Why?
|
| Comorbidity | 2 | 2003 | 737 | 0.050 |
Why?
|
| Genotype | 2 | 2015 | 800 | 0.040 |
Why?
|
| Medicaid | 1 | 2021 | 143 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 485 | 0.030 |
Why?
|
| Middle East | 1 | 2015 | 21 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 82 | 0.030 |
Why?
|
| Recurrence | 2 | 2006 | 152 | 0.030 |
Why?
|
| Health Surveys | 1 | 2015 | 405 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2015 | 430 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 972 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2012 | 9 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2012 | 87 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 70 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 150 | 0.020 |
Why?
|
| Plasmodium falciparum | 1 | 2011 | 144 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 6 | 0.020 |
Why?
|
| Donor Selection | 1 | 2009 | 9 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2011 | 209 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2009 | 27 | 0.020 |
Why?
|
| Siblings | 1 | 2009 | 22 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 47 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 54 | 0.020 |
Why?
|
| Cytokines | 1 | 2012 | 678 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 13872 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 1600 | 0.020 |
Why?
|
| Erythromycin | 1 | 2006 | 14 | 0.020 |
Why?
|
| Clindamycin | 1 | 2006 | 13 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 116 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2006 | 90 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 245 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 1604 | 0.010 |
Why?
|
| Phylogeny | 1 | 2006 | 769 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 1857 | 0.010 |
Why?
|
| Prevalence | 1 | 2002 | 1612 | 0.010 |
Why?
|